Abstract
Indomethacin was incorporated in an original emulsion formulation stabilized by a combination of phospholipids and an amphoteric surfactant, lauroamphodiacetate. The solubility of indomethacin in the various emulsion phases was pH-dependent. The pH of the emulsion was adjusted to 5.8 in order to promote localization of the drug in the oil phase and prevent drug ionization. Ionization would increase drug aqueous solubility and result in indomethacin precipitation. Optimal manufacturing conditions were identified yielding an emulsion with a mean droplet size of 110 ± 20 nm and a zeta potential value of -50 mV. The emulsion was found to be chemically and physically stable for more than 5 months at 4°C. The results of the ocular tolerance study in rabbit eye indicated that hourly administration of the emulsion vehicle was well tolerated without any toxic or inflammatory response to the ocular surface during the 5 days of the study. Scanning electron microscopy revealed a normal corneal surface resembling that of the animals treated with physiological saline. The penetration rate of indomethacin through excised rabbit eye cornea from the emulsion and from a marketed product (Indocollyre®) were determined and compared using a novel mounted corneal diffusion assembly. It was shown that the apparent corneal permeability coefficient of indomethacin incorporated in the emulsion was 3.8 times greater than that of indomethacin in the marketed aqueous solution. The increase in corneal drug permeation could be attributed to various causes that are discussed in the manuscript.
| Original language | English |
|---|---|
| Pages (from-to) | 55-64 |
| Number of pages | 10 |
| Journal | Journal of Controlled Release |
| Volume | 44 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1 Feb 1997 |
Keywords
- Corneal permeation
- Emulsion
- Indomethacin
- Stability